|
Turkish Society of Cardiology
Young Cardiologists
President
Dr. Muzaffer Değertekin
Coordinator for the
Board of Directors
Dr. Ertuğrul Okuyan
Coordinator for the
Board of Directors
Dr. Can Yücel Karabay
Members
Dr. Adem Aktan
Dr. Gülşah Aktüre
Dr. Bayram Arslan
Dr. İnanç Artaç
Dr. Ahmet Oğuz Aslan
Dr. Görkem Ayhan
Dr. Ahmet Anıl Başkurt
Dr. Özkan Bekler
Dr. Oğuzhan Birdal
Dr. Yusuf Bozkurt Şahin
Dr. Serkan Bulgurluoğlu
Dr. Ümit Bulut
Dr. Veysi Can
Dr. Mustafa Candemir
Dr. Murat Çap
Dr. Göksel Çinier
Dr. Ali Çoner
Dr. Yusuf Demir
Dr. Ömer Furkan Demir
Dr. Murat Demirci
Dr. Ayşe İrem Demirtola Mammadli
Dr. Süleyman Çağan Efe
Dr. Mehmet Akif Erdöl
Dr. Kubilay Erselcan
Dr. Kerim Esenboğa
Dr. Duygu Genç
Dr. Kemal Göçer
Dr. Elif Güçlü
Dr. Arda Güler
Dr. Duygu İnan
Dr. Hasan Burak İşleyen
Dr. Muzaffer Kahyaoğlu
Dr. Sedat Kalkan
Dr. Yücel Kanal
Dr. Özkan Karaca
Dr. Ahmet Karaduman
Dr. Mustafa Karanfil
Dr. Ayhan Kol
Dr. Fatma Köksal
Dr. Mevlüt Serdar Kuyumcu
Dr. Yunus Emre Özbebek
Dr. Ahmet Özderya
Dr. Yasin Özen
Dr. Ayşenur Özkaya İbiş
Dr. Çağlar Özmen
Dr. Selvi Öztaş
Dr. Hasan Sarı
Dr. Serkan Sivri
Dr. Ali Uğur Soysal
Dr. Hüseyin Tezcan
Dr. Nazlı Turan
Dr. Berat Uğuz
Dr. Örsan Deniz Urgun
Dr. İdris Yakut
Dr. Mustafa Yenerçağ
Dr. Mehmet Fatih Yılmaz
Dr. Yakup Yiğit
Dr. Mehmet Murat Yiğitbaşı
Bulletin Editors
Dr. Muzaffer Değertekin
Dr. Bülent Mutlu
Dr. Süleyman Çağan Efe
Dr. Duygu İnan
Dr. Alper Karakuş
Dr. Sedat Kalkan
Dr. Göksel Çinier
Contributors
Dr. Selin Çakır
Dr. Ezgi Güzel
Dr. Numan Kılıç
Dr. Cansu Öztürk
Dr. Bilal Ülker
Dr. Gözde Yılmaz
|
| |
|
|
|
STOP-CA Trial: Statin Therapy Associated with Reduced Heart Dysfunction from AnthracyclinesTürk Kardiyoloji Derneği Genç Kardiyologlar Bülteni - STOP-CA Trial: Statin Therapy Associated with Reduced Heart Dysfunction from Anthracyclines (Dr. Bilal Ülker)STOP-CA Trial: Statin Therapy Associated with Reduced Heart Dysfunction from Anthracyclines
Dr. Bilal Ülker
Published in Congress: ACC 2023
Objective:
It was aimed to investigate the effect of atorvastatin treatment on cardiac functions in patients receiving anthracycline-containing chemotherapy regimen in the treatment of lymphoma.
Methods:
The STOP-CA study was a multicenter, randomized, double-blind, placebo-controlled trial. The study included 300 patients (mean age 52 years, 47% female) with lymphoma treated with anthracycline at a mean dose of 300 mg/m2 and had a left ventricular ejection fraction (LVEF) of 63%. Participants were randomized to receive atorvastatin 40mg daily or placebo, starting before the first anthracycline dose and continuing for 12 months. A total of 286 patients (95%) completed the study.
Results:
The primary endpoint was defined as the proportion of patients with LVEF below 55% with a reduction in LVEF of more than 10%, and at the end of 12 months, 9% of the atorvastatin group and 22% of the placebo group had this outcome (p=0.002), indicating that the primary endpoint was almost three times more likely to occur for patients receiving placebo. A secondary outcome of the proportion of patients with an EF less than 55% with a greater than 5% drop in LVEF in each group was also investigated, with an incidence of 13% in the atorvastatin group and 29% in the placebo group (p=0.001).
Discussion:
The STOP-CA demonstrated that patients receiving an anthracycline-containing chemotherapy regimen for the treatment of lymphoma were less likely to have impaired cardiac function after taking atorvastatin for 12 months. The researchers concluded that further research is needed to determine the subgroups that would benefit most from statin therapy, whether statin therapy prevents symptomatic heart failure, the timing and duration of statin therapy during cancer treatment, and whether this benefit extends to other cancer types.
|
